Friday, June 3, 2016

BRIEF-Mylan and Biocon to present phase 3 trastuzumab biosimilar data at ASCO annual meeting

* Mylan and Biocon to present phase 3 trastuzumab biosimilar

data at the American Society Of Clinical Oncology (ASCO) annual

meeting

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)